OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Earnings for OncoCyte Corporation (OCX)
Earnings in 2023 (TTM): $-24,855,000
According to OncoCyte Corporation's latest financial reports the company's current earnings (TTM) are $-24,855,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of OncoCyte Corporation
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-24,855,000 | $-27,781,000 |
| 2022 | $-18,612,000 | $-73,440,000 |
| 2021 | $-73,358,000 | $-64,097,000 |
| 2020 | $-31,186,000 | $-29,932,000 |
| 2019 | $-22,426,000 | $-22,329,000 |
| 2018 | $-15,754,000 | $-15,754,000 |
| 2017 | $-19,375,000 | $-19,375,000 |
| 2016 | $-11,168,000 | $-11,168,000 |
| 2015 | $-8,735,000 | $-8,735,000 |
| 2014 | $-4,986,000 | $-4,986,000 |
| 2013 | $-3,495,000 | $-3,495,000 |